U.S. markets close in 3 hours 52 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
71.35+0.33 (+0.46%)
As of 12:07PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close71.02
Open71.88
Bid71.29 x 1800
Ask71.34 x 1000
Day's Range71.19 - 71.90
52 Week Range49.24 - 73.81
Volume332,948
Avg. Volume945,178
Market Cap166.082B
Beta (5Y Monthly)0.30
PE Ratio (TTM)28.98
EPS (TTM)2.46
Earnings DateN/A
Forward Dividend & Yield1.04 (1.46%)
Ex-Dividend DateAug 14, 2020
1y Target Est72.35
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programmeBagsværd, Denmark, 19 October 2020 – On 6 August 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.Under the programme initiated 6 August 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 6 August 2020 to 28 October 2020.Since the announcement as of 12 October 2020, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKK Accumulated, last announcement5,174,491 2,198,109,903 12 October 2020105,000460.0448,304,447 13 October 2020105,000465.0548,830,248 14 October 2020105,000459.6248,259,589 15 October 2020105,000450.5447,306,483 16 October 2020105,000449.9947,249,259 Accumulated under the programme5,699,491 2,438,059,929 The details for each transaction made under the share repurchase programme are published on novonordisk.com.With the transactions stated above, Novo Nordisk owns a total of 25,747,394 B shares of DKK 0.20 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 16 October 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 25,758,670 B shares at an average share price of DKK 426.61 per B share equal to a transaction value of DKK 10,988,847,660.Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,100 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.Further informationMedia:   Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com Ken Inchausti (US)+1 609 240 9429kiau@novonordisk.com     Investors:   Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com Mark Joseph Root+45 3079 4211mjhr@novonordisk.com Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement no. 60 / 2020 Attachment * CA201019_Safe_Harbour

  • Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's
    Zacks

    Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's

    Q3 Earnings Scorecard and Top Research Reports for Apple, PepsiCo & McDonald's

  • IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
    Benzinga

    IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week

    This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week.Codiak Biosciences: Clinical stage biopharmaceutical Codiak Biosciences (NASDAQ: CDAK) plans to sell 5.5 million shares at a price point of $14 to $16. The company initiated clinical trials for its lead products in September to address solid tumors.Codiak has collaborations with Jazz Pharmaceuticals (NASDAQ: JAZZ) and Sarepta Therapeutics (NASDAQ: SRPT). Jazz Pharmaceuticals paid Codiak $56 million upfront with $1 billion in tiered milestone royalties. Sarepta paid $10 million upfront and will pay up to $192.5 million per target in milestones along with tiered royalties.Array Technologies: Trackers move solar panels throughout the day to maintain the optimal orientation of the sun. Array Technologies (NASDAQ: ARRY), one of the world's largest tracker manufacturers, plans to sell 33.75 million shares at a price point of $19 to $21. The majority of shares sold (26.75 million) will come from selling stockholders. Solar power is the fastest growing form of electricity in the U.S. with compound annual growth of 20% from 2014 to 2019. Trackers saw compound annual growth of 35% from 2017 to 2019.Array Technologies reported revenue of $647.9 million in fiscal 2019, which was more than double the $290.8 million reported the prior year. Revenue for the first six months of 2020 was $552.6 million. The company reported net income of $39.7 million in fiscal 2019 and $76.1 million for the first six months of 2020.Miniso Group Holding: Chinese retailer Miniso Group Holding (NYSE: MNSO) plans to sell 30.4 million ADS at a price range of $16.50 to $18.50. The company is one of the largest global branded variety retailers. Miniso has over 4,200 stores across 80 countries, opening its first store in China in 2013. There are more than 2,500 Miniso stores in China. Revenue was $1.3 billion for the last fiscal year, which was down 4.4% year-over-year. The company saw nearly 68% of revenue from its operations in China.Spinal Elements Holdings: Medical device company Spinal Elements Holdings (NASDAQ: SPEL) plans to sell 7.7 million shares at a price point of $13 to $15. The company helps with minimally invasive surgeries. Its main market of spine surgery is expected to grow globally from $17.6 billion in 2018 to $22.5 billion in 2024.An area of growth for the company is expanding its international presence. Nine month revenue for the current fiscal year is expected to be $66.2 million to $66.6 million, down from $69.8 million in the prior year.Opthea Ltd.: Clinical stage Opthea Ltd. (NASDAQ: OPTN), targeting retinal diseases, plans on selling 9.3 million ADS at a price of around $17. The company has a Phase 3 ready product with its OPT-302 targeting age-related macular degeneration. Two Phase 3 trials are expected to enter Phase 3 in the first half of 2021. Top line results are expected in 2023.Ranibizumab (Lucentis) and Aflibercept (Eylea) are the current standard of care for Wet AMD, which effects 1 million people in the U.S. and 2.5 million in Europe. These two options accounted for $11.9 billion in sales in 2019. Lucentis is sold by Genetech, a Roche Holding (OTCQX: RHHBY), in the U.S. Eylea is sold by Regeneron Pharmaceuticals (NASDAQ: REGN).Eargo Inc.: Hearing aid company Eargo Inc. (NASDAQ: EAR) plans to sell 6,666,667 shares at a price point of $14 to $16. The company believes it is the first and only virtually invisible, rechargeable, in-canal, FDA regulated hearing aid.Over 42,000 devices have been sold by the company as of June. The company estimates 43 million adults in the U.S. suffer from some form of hearing loss, with only 27% owning a hearing aid.Behind the ear hearing aids dominate the market with 88% share in 2019, compared to 12% for in the ear aids. Eargo has seen revenue grow at an average annual rate of 122.6% for the last three years with $32.8 million in fiscal 2019. The first six months of 2020 had revenue of $28.6 million. Third quarter revenue is estimated to be in the range of $18.0 to $18.3 million.Praxis Precision Medicines: Clinical stage company Praxis Precision Medicines (NASDAQ:PRAX) is targeting depression, epilepsy, movement disorders and pain syndromes. The company's lead candidate PRAX-114 is in Phase 2a trials. The company expects topline readouts from three of its five current programs by the end of 2021.PRAX-222 is a pre-clinical collaboration with Ionis Pharmaceuticals (NASDAQ: IONS). Novo Holdings, a Novo Nordisk (NYSE: NVO) unit, is a top shareholder in the company along with Blackstone Group (NYSE: BX). The company plans on selling 7.4 million shares at a price point of $16 to $18.Tarsus Pharmaceuticals: Clinical stage Tarsus Pharmaceuticals (NASDAQ:TARS) plans on selling 5 million shares at a price point of $15 to $17. The company's lead drug is TP-03 in Phase 2b/3 trials as a treatment of blepharitis. A Phase 3 is expected to enter Phase 3 in 2021. If approved, this would be the first FDA approved treatment for Demoodex blepharitis. Tarsus Pharmaceuticals is also targeting lyme disease and malaria treatments in pre-clinical studies.Allgos Therapeutics: Clinical stage biopharmaceutical company Allgos Therapeutics (NASDAQ:ALGS) plans on selling 10 million shares at a price point of $14 to $16. The company is targeting chronic Hepatitis B and non-alcoholic steatohepatitis (NASH).Allgos also has a treatment it is targeting for SARS-Cov-2, the virus responsible for Covid-19. ALG-010133 is in Phase 1 trials for chronic Hepatitis B, a condition that effects 290 million people worldwide. Novo Holdings and Roche are investors in the company.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * FuboTV Uplisting, Kronos Bio Highlight This Week's IPOs * Ligand: The Small Cap Powering Gilead's Remdesivir(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.